侵襲性真菌感染症の世界市場レポート 2025年

侵襲性真菌感染症の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.8％で96億米ドルに成長します。予測期間の成長は、世界の健康への備え、公衆衛生教育、新規抗真菌剤、気候変動の影響、学際的アプローチに起因すると考えられます。予測期間における主な動向としては、診断技術の進歩、オーダーメイドの治療アプローチ、患者中心の治療、抗真菌薬の併用療法、医薬品開発のための共同研究などが挙げられます。

ヒト免疫不全ウイルス（HIV）に罹患する人口の増加が予測されることから、侵襲性真菌感染症市場は今後数年間で拡大すると予想されます。HIVは、病気や感染症と闘う免疫系の能力を低下させるウイルスです。HIV感染者やAIDS感染者など免疫系が低下している人の数が増加するにつれて、侵襲性真菌感染症に対する感受性も高まっています。この急増は、製造業者にとって、特殊でより効果的な抗真菌薬を開発・供給する機会を生み出します。2023年7月の国連合同エイズ計画（UNAIDS）によると、HIVとともに生きる世界の人口は2022年には3,900万人に増加し、2020年の3,770万人から3.17％増加しました。さらに、2022年には約130万人の新規HIV感染が報告されました。したがって、HIVに罹患する人口の増加が予測され、侵襲性真菌感染症市場の成長を促進すると予想されます。

がん患者の増加は、今後の侵襲性真菌感染症市場の拡大に拍車をかけると予測されています。侵襲性真菌感染症（IFI）は、がん患者、特に免疫力が低下した患者にとって重篤で生命を脅かす可能性のある合併症を引き起こします。がんサバイバーの人口が増加していることは、これらの人々のIFIのリスクを増大させている重要な要因です。2022年11月に米国国立がん研究所が報告したように、2040年までにがんサバイバーは約2,600万人になると予測されています。さらに、がんと診断されてから5年以上生存している人の数は30％近く急増し、その後の10年間で1,630万人に達すると予想されています。その結果、がん患者数と生存者数の増加が侵襲性真菌感染症市場成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界侵襲性真菌感染症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の侵襲性真菌感染症市場：成長率分析
• 世界の侵襲性真菌感染症市場の実績：規模と成長, 2019-2024
• 世界の侵襲性真菌感染症市場の予測：規模と成長, 2024-2029, 2034F
• 世界侵襲性真菌感染症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の侵襲性真菌感染症市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カンジダ血症と侵襲性カンジダ症
• 腹腔内カンジダ症
• クリプトコッカス髄膜炎
• 食道カンジダ症
• ヒストプラズマ症急性肺
• その他の病気の種類
• 世界の侵襲性真菌感染症市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ポリエン
• トリアゾール
• エキノキャンディン
• フルシトシン
• その他の薬剤の種類
• 世界の侵襲性真菌感染症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の侵襲性真菌感染症市場、カンジダ血症と侵襲性カンジダ症のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血流感染症
• 全身性カンジダ症
• 世界の侵襲性真菌感染症市場腹腔内カンジダ症の分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腹膜カンジダ症
• 膿瘍の形成
• 世界の侵襲性真菌感染症市場クリプトコッカス髄膜炎の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性クリプトコッカス髄膜炎
• 二次性クリプトコッカス髄膜炎
• 世界の侵襲性真菌感染症市場食道カンジダ症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性食道カンジダ症
• 慢性食道カンジダ症
• 世界の侵襲性真菌感染症市場急性肺ヒストプラズマ症のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 播種性ヒストプラズマ症
• 慢性肺ヒストプラズマ症
• 世界の侵襲性真菌感染症市場、その他の疾患タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アスペルギルス症
• ムコール症
• その他の稀な真菌感染症

第7章 地域別・国別分析

• 世界の侵襲性真菌感染症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の侵襲性真菌感染症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 侵襲性真菌感染症市場：競合情勢
• 侵襲性真菌感染症市場：企業プロファイル
  • Alphabet Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK plc
• Gilead Sciences Inc.
• Siemens Healthineers
• Mylan N.V.
• Astellas Pharma Inc.
• Quest Diagnostics Incorporated
• Sun Pharmaceutical Industries Ltd.
• BioMerieux SA
• BioMarin Pharmaceutical Inc.
• Xellia Pharmaceuticals
• Basilea Pharmaceutica
• Cidara Therapeutic Inc.
• Pulmocide Ltd.
• NovaBiotics Ltd
• F2G Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 侵襲性真菌感染症市場2029：新たな機会を提供する国
• 侵襲性真菌感染症市場2029：新たな機会を提供するセグメント
• 侵襲性真菌感染症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Invasive fungal infections are severe diseases caused by pathogenic fungi that penetrate and spread within the body, extending beyond the point of initial infection. These infections involve the penetration of fungal organisms into deeper layers of tissue, including the bloodstream, organs, or other body structures. The treatment of invasive fungal infections typically includes the use of antifungal medications and, in certain instances, surgical procedures to excise infected tissue.

The main types of invasive fungal infections encompass candidemia and invasive candidiasis, intraabdominal candidiasis, cryptococcal meningitis, esophageal candidiasis, histoplasmosis acute pulmonary, and others. Candidemia and invasive candidiasis, for instance, are infections caused by Candida fungus that can affect various parts of the body, including the blood, heart, brain, eyes, bones, or other organs. Treatment involves the use of different drug types, such as polyenes, triazoles, echinocandins, flucytosine, and others, and is administered by various end-users, including hospitals, homecare, specialty clinics, and others.

The invasive fungal infections market research report is one of a series of new reports from The Business Research Company that provides invasive fungal infections market statistics, including invasive fungal infections industry global market size, regional shares, competitors with a invasive fungal infections market share, detailed invasive fungal infections market segments, market trends and opportunities, and any further data you may need to thrive in the invasive fungal infections industry. This invasive fungal infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The invasive fungal infections market size has grown steadily in recent years. It will grow from $7.58 billion in 2024 to $7.96 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to global spread of infections, hematopoietic stem cell transplants, aging population, hospital-acquired infections, environmental factors.

The invasive fungal infections market size is expected to see steady growth in the next few years. It will grow to $9.6 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to global health preparedness, public health education, novel antifungal agents, climate change impact, multidisciplinary approaches. Major trends in the forecast period include advancements in diagnostic technologies, tailored therapeutic approaches, patient-centric care, combination antifungal therapies, collaborations for drug development.

The projected increase in the population afflicted by Human Immunodeficiency Virus (HIV) is anticipated to propel the expansion of the invasive fungal infection market in the coming years. HIV is a virus that compromises the immune system's ability to combat diseases and infections. As the number of individuals with compromised immune systems, including those affected by HIV or AIDS, rises, susceptibility to invasive fungal infections escalates. This surge creates opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS) in July 2023, the global population living with HIV increased to 39 million in 2022, marking a 3.17% rise from 37.7 million in 2020. Additionally, approximately 1.3 million new HIV infections were reported in 2022. Hence, the anticipated rise in the population affected by HIV is expected to drive the growth of the invasive fungal infection market.

The mounting number of cancer patients is forecasted to fuel the expansion of the invasive fungal infections market in the future. Invasive fungal infections (IFIs) pose severe and potentially life-threatening complications for cancer patients, particularly those with weakened immune systems. The growing population of cancer survivors is a significant factor contributing to the increased risk of IFIs among these individuals. As reported by the National Cancer Institute in November 2022, it is projected that by 2040, there will be approximately 26.0 million cancer survivors. Furthermore, the number of individuals who have survived five or more years after a cancer diagnosis is expected to surge by nearly 30%, reaching 16.3 million over the subsequent decade. Consequently, the escalating number of cancer patients and survivors stands as a driving force behind the growth of the invasive fungal infections market.

Leading companies in the invasive fungal infection market are increasingly focusing on innovative treatments such as Zisavel capsules to enhance therapeutic efficacy, improve patient outcomes, and expand access for individuals affected by serious fungal infections. Zisavel capsules, a generic form of the antifungal isavuconazole, target invasive aspergillosis and mucormycosis-two life-threatening fungal infections. These 100 mg capsules offer a cost-effective alternative, potentially increasing accessibility for patients who require antifungal treatments. For example, in October 2023, BDR Pharmaceuticals, an India-based company specializing in generic and specialty pharmaceuticals, launched Zisavel capsules specifically for treating invasive aspergillosis and mucormycosis. This introduction is expected to reduce treatment costs significantly compared to existing options like voriconazole and posaconazole, making effective antifungal therapy more affordable and accessible.

In August 2023, Sandoz, a Germany-based pharmaceutical company known for its expertise in generic medicines and biosimilars, acquired Astellas Pharma Inc. for an undisclosed amount. This acquisition allows Sandoz to strengthen its portfolio of generics and biosimilars, broaden its market reach, and capitalize on synergies to foster growth and innovation in the pharmaceutical industry. Astellas Pharma Inc., a Japan-based pharmaceutical company, specializes in the research, development, manufacturing, and commercialization of innovative medications. Through this strategic acquisition, Sandoz aims to bolster its position in the global market and advance its offerings across various therapeutic areas.

Major companies operating in the invasive fungal infections market report are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK PLC, Gilead Sciences Inc., Siemens Healthineers, Mylan N.V., Astellas Pharma Inc., Quest Diagnostics Incorporated, Sun Pharmaceutical Industries Ltd., BioMerieux SA, BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd., F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB

North America was the largest region in the invasive fungal infections market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the invasive fungal infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The invasive fungal infections market consists of revenues earned by entities by providing services such as diagnostic testing, clinical research and development, educational programs, and awareness campaign services. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive fungal infections market also includes sales of azoles, allylamines, and morpholines, which are used in treating invasive fungal infections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Invasive Fungal Infections Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on invasive fungal infections market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for invasive fungal infections ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The invasive fungal infections market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Candidemia And Invasive Candidiasis; Intra Abdominal Candidiasis; Cryptococcal Meningitis; Esophageal Candidiasis; Histoplasmosis Acute Pulmonary; Other Disease Type
• 2) By Drug Type: Polyenes; Triazoles; Echinocandins; Flucytosine; Other Drug Type
• 3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Candidemia And Invasive Candidiasis: Bloodstream Infections; Disseminated Candidiasis
• 2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis; Abscess Formation
• 3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis; Secondary Cryptococcal Meningitis
• 4) By Esophageal Candidiasis: Acute Esophageal Candidiasis; Chronic Esophageal Candidiasis
• 5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis; Chronic Pulmonary Histoplasmosis
• 6) By Other Disease Types: Aspergillosis; Mucormycosis; Other Rare Fungal Infections
• Companies Mentioned: Pfizer Inc.; Merck And Co. Inc.; Bayer AG; Abbott Laboratories; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Invasive Fungal Infections Market Characteristics

3. Invasive Fungal Infections Market Trends And Strategies

4. Invasive Fungal Infections Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Invasive Fungal Infections Growth Analysis And Strategic Analysis Framework

• 5.1. Global Invasive Fungal Infections PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Invasive Fungal Infections Market Growth Rate Analysis
• 5.4. Global Invasive Fungal Infections Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Invasive Fungal Infections Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Invasive Fungal Infections Total Addressable Market (TAM)

6. Invasive Fungal Infections Market Segmentation

• 6.1. Global Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Candidemia And Invasive Candidiasis
• Intra Abdominal Candidiasis
• Cryptococcal Meningitis
• Esophageal Candidiasis
• Histoplasmosis Acute Pulmonary
• Other Disease Type
• 6.2. Global Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polyenes
• Triazoles
• Echinocandins
• Flucytosine
• Other Drug Type
• 6.3. Global Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.4. Global Invasive Fungal Infections Market, Sub-Segmentation Of Candidemia And Invasive Candidiasis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bloodstream Infections
• Disseminated Candidiasis
• 6.5. Global Invasive Fungal Infections Market, Sub-Segmentation Of Intra-Abdominal Candidiasis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peritoneal Candidiasis
• Abscess Formation
• 6.6. Global Invasive Fungal Infections Market, Sub-Segmentation Of Cryptococcal Meningitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Cryptococcal Meningitis
• Secondary Cryptococcal Meningitis
• 6.7. Global Invasive Fungal Infections Market, Sub-Segmentation Of Esophageal Candidiasis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Esophageal Candidiasis
• Chronic Esophageal Candidiasis
• 6.8. Global Invasive Fungal Infections Market, Sub-Segmentation Of Histoplasmosis Acute Pulmonary, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Disseminated Histoplasmosis
• Chronic Pulmonary Histoplasmosis
• 6.9. Global Invasive Fungal Infections Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aspergillosis
• Mucormycosis
• Other Rare Fungal Infections

7. Invasive Fungal Infections Market Regional And Country Analysis

• 7.1. Global Invasive Fungal Infections Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Invasive Fungal Infections Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Invasive Fungal Infections Market

• 8.1. Asia-Pacific Invasive Fungal Infections Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Invasive Fungal Infections Market

• 9.1. China Invasive Fungal Infections Market Overview
• 9.2. China Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Invasive Fungal Infections Market

• 10.1. India Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Invasive Fungal Infections Market

• 11.1. Japan Invasive Fungal Infections Market Overview
• 11.2. Japan Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Invasive Fungal Infections Market

• 12.1. Australia Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Invasive Fungal Infections Market

• 13.1. Indonesia Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Invasive Fungal Infections Market

• 14.1. South Korea Invasive Fungal Infections Market Overview
• 14.2. South Korea Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Invasive Fungal Infections Market

• 15.1. Western Europe Invasive Fungal Infections Market Overview
• 15.2. Western Europe Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Invasive Fungal Infections Market

• 16.1. UK Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Invasive Fungal Infections Market

• 17.1. Germany Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Invasive Fungal Infections Market

• 18.1. France Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Invasive Fungal Infections Market

• 19.1. Italy Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Invasive Fungal Infections Market

• 20.1. Spain Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Invasive Fungal Infections Market

• 21.1. Eastern Europe Invasive Fungal Infections Market Overview
• 21.2. Eastern Europe Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Invasive Fungal Infections Market

• 22.1. Russia Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Invasive Fungal Infections Market

• 23.1. North America Invasive Fungal Infections Market Overview
• 23.2. North America Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Invasive Fungal Infections Market

• 24.1. USA Invasive Fungal Infections Market Overview
• 24.2. USA Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Invasive Fungal Infections Market

• 25.1. Canada Invasive Fungal Infections Market Overview
• 25.2. Canada Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Invasive Fungal Infections Market

• 26.1. South America Invasive Fungal Infections Market Overview
• 26.2. South America Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Invasive Fungal Infections Market

• 27.1. Brazil Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Invasive Fungal Infections Market

• 28.1. Middle East Invasive Fungal Infections Market Overview
• 28.2. Middle East Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Invasive Fungal Infections Market

• 29.1. Africa Invasive Fungal Infections Market Overview
• 29.2. Africa Invasive Fungal Infections Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Invasive Fungal Infections Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Invasive Fungal Infections Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Invasive Fungal Infections Market Competitive Landscape And Company Profiles

• 30.1. Invasive Fungal Infections Market Competitive Landscape
• 30.2. Invasive Fungal Infections Market Company Profiles
  • 30.2.1. Alphabet Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Invasive Fungal Infections Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. Gilead Sciences Inc.
• 31.3. Siemens Healthineers
• 31.4. Mylan N.V.
• 31.5. Astellas Pharma Inc.
• 31.6. Quest Diagnostics Incorporated
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. BioMerieux SA
• 31.9. BioMarin Pharmaceutical Inc.
• 31.10. Xellia Pharmaceuticals
• 31.11. Basilea Pharmaceutica
• 31.12. Cidara Therapeutic Inc.
• 31.13. Pulmocide Ltd.
• 31.14. NovaBiotics Ltd
• 31.15. F2G Ltd.

32. Global Invasive Fungal Infections Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Invasive Fungal Infections Market

34. Recent Developments In The Invasive Fungal Infections Market

35. Invasive Fungal Infections Market High Potential Countries, Segments and Strategies

• 35.1 Invasive Fungal Infections Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Invasive Fungal Infections Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Invasive Fungal Infections Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer